ketanserin has been researched along with Tics in 1 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
Tics: Habitual, repeated, rapid contraction of certain muscles, resulting in stereotyped individualized actions that can be voluntarily suppressed for only brief periods. They often involve the face, vocal cords, neck, and less often the extremities. Examples include repetitive throat clearing, vocalizations, sniffing, pursing the lips, and excessive blinking. Tics tend to be aggravated by emotional stress. When frequent they may interfere with speech and INTERPERSONAL RELATIONS. Conditions which feature frequent and prominent tics as a primary manifestation of disease are referred to as TIC DISORDERS. (From Adams et al., Principles of Neurology, 6th ed, pp109-10)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty adults with Tourette's syndrome and 20 healthy control subjects were investigated with PET-[18F]altanserin using a bolus-infusion protocol." | 1.34 | Cerebral 5-HT2A receptor binding is increased in patients with Tourette's syndrome. ( Bolwig, TG; Hansen, ES; Haugbøl, S; Knudsen, GM; Nielsen, FA; Pinborg, LH; Regeur, L; Skovgaard, LT; Svarer, C, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haugbøl, S | 1 |
| Pinborg, LH | 1 |
| Regeur, L | 1 |
| Hansen, ES | 1 |
| Bolwig, TG | 1 |
| Nielsen, FA | 1 |
| Svarer, C | 1 |
| Skovgaard, LT | 1 |
| Knudsen, GM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label, Proof-of-Principle, Pilot Study to Evaluate Pimavanserin for the Treatment of Motor and Behavioral Symptoms of Tourette Syndrome[NCT04794413] | Early Phase 1 | 10 participants (Actual) | Interventional | 2018-11-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for ketanserin and Tics
| Article | Year |
|---|---|
Cerebral 5-HT2A receptor binding is increased in patients with Tourette's syndrome.
Topics: Adolescent; Adult; Brain Chemistry; Female; Humans; Ketanserin; Magnetic Resonance Imaging; Male; Mi | 2007 |